|
|
|
|
| LEADER |
00000pam a2200000 a 4500 |
| 001 |
5128434 |
| 003 |
ICU |
| 005 |
20041210121400.0 |
| 008 |
031112s2004 njua b 001 0 eng |
| 010 |
|
|
|a 2003024925
|
| 020 |
|
|
|a 1588292282 (alk. paper)
|
| 020 |
|
|
|a 1592597394 (E-ISBN)
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC
|d NhCcYBP
|d OCoLC
|d OrLoB-B
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RC271.C5
|b A6722 2004
|
| 060 |
1 |
0 |
|a QV 269
|b A62953 2004
|
| 082 |
0 |
0 |
|a 616.99/4061
|2 22
|
| 245 |
0 |
0 |
|a Anticancer drug development guide :
|b preclinical screening, clinical trials, and approval /
|c edited by Beverly A. Teicher, Paul A. Andrews.
|
| 250 |
|
|
|a 2nd ed.
|
| 260 |
|
|
|a Totowa, N.J. :
|b Humana Press,
|c c2004.
|
| 300 |
|
|
|a xiv, 450 p. :
|b ill. ;
|c 26 cm. +
|e 1 CD-ROM (4 3/4 in.).
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 440 |
|
0 |
|a Cancer drug discovery and development
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 505 |
0 |
0 |
|g 1.
|t High-volume screening /
|r Michel Page --
|g 2.
|t High-throughput screening in industry /
|r Michael D. Boisclair, David A. Egan, Kety Huberman and Ralph Infantino --
|g 3.
|t The NCI human tumor cell line (60-cell) screen: concept, implementation, and applications /
|r Michael R. Boyd --
|g 4.
|t Human tumor screening /
|r Axel-R. Hanauske, Susan G. Hilsenbeck and Daniel D. Von Hoff --
|g 5.
|t Murine L1210 and P388 leukemias /
|r William R. Waud --
|g 6.
|t In vivo methods for screening and preclinical testing: use of rodent solid tumors for drug discovery /
|r Thomas Corbett, Lisa Polin, Patricia LoRusso, Fred Valeriote, Chiab Panchapor, Susan Pugh, Kathryn White, Juiwanna Knight, Lisa Demchik, Julie Jones, Lynne Jones and Loretta Lisow --
|g 7.
|t Human tumor xenograft models in NCI drug development /
|r Michael C. Alley, Melinda G. Hollingshead, Donald J. Dykes and William R. Waud --
|g 8.
|t NCI specialized procedures in preclinical drug evaluations /
|r Melinda G. Hollingshead, Michael C. Alley, Gurmeet Kaur, Christine M. Pacula-Cox and Sherman F. Stinson --
|g 9.
|t Patient-like orthotopic metastatic models of human cancer /
|r Robert M. Hoffman --
|g 10.
|t Preclinical models for combination therapy /
|r Beverly A. Teicher --
|g 11.
|t Models for biomarkers and minimal residual tumor /
|r Beverly A. Teicher --
|g 12.
|t Spontaneously occurring tumors in companion animals as models for drug development /
|r David M. Vail and Douglas H. Thamm --
|g 13.
|t Nonclinical testing: from theory to practice /
|r Denis Roy and Paul A. Andrews --
|g 14.
|t Nonclinical testing for oncology drug products /
|r Paul A. Andrews and Denis Roy --
|g 15.
|t Nonclinical testing for oncology biologic products /
|r Carolyn M. Laurencot, Denis Roy and Paul A. Andrews --
|g 16.
|t Working with the national cancer institute /
|r Paul Thambi and Edward A. Sausville --
|g 17.
|t Phase I trial design and methodology for anticancer drugs /
|r Patrick V. Acevedo, Deborah L. Toppmeyer and Eric H. Rubin --
|g 18.
|t Phase II trials: conventional design and novel strategies in the era of targeted therapies /
|r Keith T. Flaherty and Peter J. O'Dwyer --
|g 19.
|t Drug development in europe: the academic perspective /
|r Chris Twelves, Mike Bibby, Denis Lacombe and Sally Burtles --
|g 20.
|t The phase III clinical cancer trial /
|r Ramzi N. Dagher and Richard Pazdur --
|g 21.
|t Assessing tumor-related symptoms and health-related quality of life in cancer clinical trials: a regulatory perspective /
|r Judy H. Chiao, Grant Williams and Donna Griebel --
|g 22.
|t The role of the oncology drug advisory committee in the FDA review process for oncologic products /
|r Leslie A. Vaccari --
|g 23.
|t FDA role in cancer drug development and requirements for approval /
|r Susan Flamm Honig.
|
| 538 |
|
|
|a System requirements: Serial Number: 4I5Z-29S4-GJ85-NF44
|
| 650 |
|
0 |
|a Antineoplastic agents
|x Development.
|0 http://id.loc.gov/authorities/subjects/sh97008449
|
| 650 |
1 |
2 |
|a Antineoplastic Agents
|x standards.
|
| 650 |
2 |
2 |
|a Clinical Trials as Topic.
|
| 650 |
2 |
2 |
|a Drug Approval.
|
| 650 |
2 |
2 |
|a Drug Design.
|
| 650 |
2 |
2 |
|a Drug Evaluation, Preclinical.
|
| 650 |
|
7 |
|a Antineoplastic agents
|x Development.
|2 fast
|0 http://id.worldcat.org/fast/fst00810599
|
| 700 |
1 |
|
|a Teicher, Beverly A.,
|d 1952-
|0 http://id.loc.gov/authorities/names/n92806107
|1 http://viaf.org/viaf/84496164
|
| 700 |
1 |
|
|a Andrews, Paul A.
|0 http://id.loc.gov/authorities/names/n2003130791
|1 http://viaf.org/viaf/271322820
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 903 |
|
|
|a Hathi
|
| 035 |
|
|
|a (OCoLC)53443077
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 07b286d5-f50c-5fdc-bbc4-9fea85787345
|s 1e0d524b-22c4-53a1-9073-e791e51ffb34
|
| 928 |
|
|
|t Library of Congress classification
|a RC271.C5A6722 2004
|l JCL
|c JCL-Sci
|i 4805833
|
| 928 |
|
|
|t Library of Congress classification
|a RC271.C5A6722 2004
|l JCL
|c JCL-SMedia
|i 4805834
|
| 927 |
|
|
|t Library of Congress classification
|a RC271.C5A6722 2004
|v text
|l JCL
|c JCL-Sci
|e WIGO
|e CRERAR
|b 64344770
|i 7661874
|
| 927 |
|
|
|t Library of Congress classification
|a RC271.C5A6722 2004
|v CDRom
|l JCL
|c JCL-SMedia
|e WIGO
|e CRERAR
|b 64347840
|i 7661875
|
